• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Two Strikes but Not Out: Deep Remission of Ulcerative Colitis with Ustekinumab After Primary Non-response to Infliximab and Vedolizumab.

作者信息

Dalal Rahul S, Ananthakrishnan Ashwin N, Hamilton Matthew J, Winter Rachel W

机构信息

Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital, Boston, MA, USA.

Harvard Medical School, Boston, MA, USA.

出版信息

Dig Dis Sci. 2021 Mar;66(3):733-737. doi: 10.1007/s10620-021-06852-3. Epub 2021 Feb 11.

DOI:10.1007/s10620-021-06852-3
PMID:33569666
Abstract
摘要

相似文献

1
Two Strikes but Not Out: Deep Remission of Ulcerative Colitis with Ustekinumab After Primary Non-response to Infliximab and Vedolizumab.两次碰壁但未出局：在对英夫利昔单抗和维多珠单抗初次治疗无反应后，使用乌司奴单抗实现溃疡性结肠炎深度缓解
Dig Dis Sci. 2021 Mar;66(3):733-737. doi: 10.1007/s10620-021-06852-3. Epub 2021 Feb 11.
2
Real-World Comparison of the Effectiveness between Ustekinumab and Vedolizumab in Patients with Ulcerative Colitis Exposed to at least One Anti-TNF Agent.在至少接受过一种抗 TNF 药物治疗的溃疡性结肠炎患者中，乌司奴单抗与维得利珠单抗有效性的真实世界比较。
J Crohns Colitis. 2024 Oct 15;18(10):1615-1621. doi: 10.1093/ecco-jcc/jjae063.
3
Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab.在接受维得利珠单抗或乌司奴单抗治疗的炎症性肠病患者中，联合治疗并未提高临床或内镜缓解率。
Clin Gastroenterol Hepatol. 2021 Jul;19(7):1366-1376.e2. doi: 10.1016/j.cgh.2020.07.012. Epub 2020 Jul 12.
4
Integrating efficacy and safety of vedolizumab compared with other advanced therapies to assess net clinical benefit of ulcerative colitis treatments: a network meta-analysis.比较维得利珠单抗与其他先进疗法的疗效和安全性，评估溃疡性结肠炎治疗的净临床获益：一项网络荟萃分析。
Expert Rev Gastroenterol Hepatol. 2021 Jun;15(6):711-722. doi: 10.1080/17474124.2021.1880319. Epub 2021 Mar 4.
5
Biologic Therapy for Ulcerative Colitis.溃疡性结肠炎的生物治疗。
Gastroenterol Clin North Am. 2020 Dec;49(4):717-729. doi: 10.1016/j.gtc.2020.08.002. Epub 2020 Sep 26.
6
Selection strategy of second-line biologic therapies in adult patients with ulcerative colitis following prior biologic treatment failure: Systematic review and meta-analysis.生物治疗失败的溃疡性结肠炎成年患者二线生物治疗选择策略：系统评价和荟萃分析。
Pharmacol Res. 2024 Apr;202:107108. doi: 10.1016/j.phrs.2024.107108. Epub 2024 Feb 24.
7
Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice.炎症性肠病患者对生物治疗（抗 TNF、Vedolizumab 和 Ustekinumab）的主要反应的预测因素：从基础科学到临床实践。
J Crohns Colitis. 2020 Jun 19;14(5):694-709. doi: 10.1093/ecco-jcc/jjz195.
8
Market Access Analysis of Biologics and Small-Molecule Inhibitors for Inflammatory Bowel Disease Among US Health Insurance Policies.生物制剂和小分子抑制剂治疗炎症性肠病在美国医保政策中的市场准入分析。
Dig Dis Sci. 2019 Sep;64(9):2478-2488. doi: 10.1007/s10620-019-05594-7. Epub 2019 Mar 28.
9
Therapeutic Drug Monitoring With Ustekinumab and Vedolizumab in Inflammatory Bowel Disease.英夫利昔单抗和维得利珠单抗治疗炎症性肠病的治疗药物监测。
Inflamm Bowel Dis. 2018 Sep 15;24(10):2165-2172. doi: 10.1093/ibd/izy134.
10
Comparative effectiveness of antitumour necrosis factor agents and vedolizumab in ulcerative colitis.抗肿瘤坏死因子药物与维多珠单抗治疗溃疡性结肠炎的疗效比较
Eur J Gastroenterol Hepatol. 2019 Jun;31(6):661-667. doi: 10.1097/MEG.0000000000001395.

本文引用的文献

1
Negative Age-Dependence of the Polygenic Risk Score Gradient for Colorectal Cancer.结直肠癌多基因风险评分梯度的负年龄依赖性
Gastroenterology. 2021 May;160(6):2214-2215. doi: 10.1053/j.gastro.2020.09.064. Epub 2020 Dec 30.
2
Novel bio-genetic predictors of response to biologic treatment in inflammatory bowel diseases.炎症性肠病生物治疗反应的新型生物遗传预测因子。
Curr Opin Pharmacol. 2020 Dec;55:132-140. doi: 10.1016/j.coph.2020.10.011. Epub 2020 Nov 26.
3
Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy.
乌司奴单抗对于溃疡性结肠炎的维持治疗 2 年是有效且安全的。
Aliment Pharmacol Ther. 2020 Dec;52(11-12):1658-1675. doi: 10.1111/apt.16119. Epub 2020 Oct 21.
4
Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre real-world cohort study.乌司奴单抗诱导治疗溃疡性结肠炎 103 例的有效性和安全性：GETAID 多中心真实世界队列研究。
Aliment Pharmacol Ther. 2020 Jun;51(11):1039-1046. doi: 10.1111/apt.15717. Epub 2020 Apr 14.
5
The Interplay between Mucosal Microbiota Composition and Host Gene-Expression is Linked with Infliximab Response in Inflammatory Bowel Diseases.黏膜微生物群组成与宿主基因表达之间的相互作用与炎症性肠病中英夫利昔单抗的反应相关。
Microorganisms. 2020 Mar 20;8(3):438. doi: 10.3390/microorganisms8030438.
6
Efficacy of ustekinumab vs. advanced therapies for the treatment of moderately to severely active ulcerative colitis: a systematic review and network meta-analysis.乌司奴单抗与中重度活动溃疡性结肠炎的高级治疗药物疗效比较：系统评价和网络荟萃分析。
Curr Med Res Opin. 2020 Apr;36(4):595-606. doi: 10.1080/03007995.2020.1716701. Epub 2020 Jan 29.
7
First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis.中重度活动型溃疡性结肠炎患者的一线和二线药物治疗：一项更新的网络荟萃分析。
Clin Gastroenterol Hepatol. 2020 Sep;18(10):2179-2191.e6. doi: 10.1016/j.cgh.2020.01.008. Epub 2020 Jan 13.
8
HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn's Disease.HLA-DQA1*05 携带与克罗恩病患者对英夫利昔单抗和阿达木单抗的药物抗体发展相关。
Gastroenterology. 2020 Jan;158(1):189-199. doi: 10.1053/j.gastro.2019.09.041. Epub 2019 Oct 7.
9
Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis.维得利珠单抗与阿达木单抗治疗中重度溃疡性结肠炎的疗效比较。
N Engl J Med. 2019 Sep 26;381(13):1215-1226. doi: 10.1056/NEJMoa1905725.
10
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis.乌司奴单抗诱导和维持溃疡性结肠炎的治疗。
N Engl J Med. 2019 Sep 26;381(13):1201-1214. doi: 10.1056/NEJMoa1900750.